

# Francis Buadi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8719336/publications.pdf>

Version: 2024-02-01

439  
papers

10,531  
citations

57631

44  
h-index

42291

92  
g-index

444  
all docs

444  
docs citations

444  
times ranked

7910  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Outcomes after biochemical or clinical progression in patients with multiple myeloma. <i>Blood Advances</i> , 2023, 7, 909-917.  | 2.5 | 7         |
| 2  | Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.  | 3.3 | 43        |
| 3  | Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2022, 36, 873-876.                               | 3.3 | 12        |
| 4  | Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2022, 36, 1058-1065.                  | 3.3 | 3         |
| 5  | Characteristics and risk factors for thrombosis in <sc>POEMS</sc> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.           | 2.0 | 5         |
| 6  | Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .                       | 2.0 | 5         |
| 7  | Kidney Transplant Outcomes of Patients With Multiple Myeloma. <i>Kidney International Reports</i> , 2022, 7, 752-762.  | 0.4 | 7         |
| 8  | A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.   | 2.8 | 30        |
| 9  | Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. <i>Leukemia</i> , 2022, 36, 1426-1428.                                 | 3.3 | 7         |
| 10 | Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .              | 2.0 | 2         |
| 11 | Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio $\geq 100$ . <i>Leukemia</i> , 2022, 36, 1429-1431.                          | 3.3 | 8         |
| 12 | Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. <i>Blood Advances</i> , 2022, , .                                  | 2.5 | 11        |
| 13 | Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2763-2772.                                       | 2.5 | 13        |
| 14 | Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 803-809.        | 1.3 | 6         |
| 15 | Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Oncology and Therapy</i> , 2022, 10, 105-122.   | 1.0 | 2         |
| 16 | Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2022, , .                              | 1.3 | 0         |
| 17 | Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2022, 12, 59. | 2.8 | 3         |
| 18 | Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. <i>Blood Advances</i> , 2022, 6, 5429-5435.                                 | 2.5 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.                 | 1.3 | 1         |
| 20 | A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021, 99, 707-715.   | 2.6 | 13        |
| 21 | Outcomes of multiple myeloma patients with $\Delta 17p$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.   | 2.0 | 2         |
| 22 | Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021, 106, 354-361.  | 1.1 | 4         |
| 23 | Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021, 106, 433-436.   | 1.1 | 3         |
| 24 | Autologous stem cell transplantation for multiple myeloma patients aged $\geq 75$ treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.  | 1.3 | 15        |
| 25 | Implications of detecting serum monoclonal protein by MASSfix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.  | 1.2 | 21        |
| 26 | Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone ( $\Delta VRd$ ) as first-line therapy in multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 330-337.   | 2.0 | 13        |
| 27 | Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 928-935.   | 1.3 | 5         |
| 28 | Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5. | 0.6 | 1         |
| 29 | Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.  | 0.6 | 2         |
| 30 | Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.   | 3.3 | 8         |
| 31 | Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). <i>Blood Cancer Journal</i> , 2021, 11, 26.   | 2.8 | 10        |
| 32 | Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021, 5, 1029-1036.  | 2.5 | 9         |
| 33 | Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 377-387.   | 1.4 | 12        |
| 34 | Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. <i>International Journal of Cancer</i> , 2021, 148, 2807-2814.  | 2.3 | 10        |
| 35 | Reply to: Comments on: Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein. <i>International Journal of Cancer</i> , 2021, 149, 743-744.                       | 2.3 | 2         |
| 36 | Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.  | 1.4 | 16        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.   | 2.8 | 25        |
| 38 | Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021, 6, 857-864.  | 0.4 | 5         |
| 39 | Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20016-e20016.   | 0.8 | 0         |
| 40 | Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.  | 3.3 | 8         |
| 41 | Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.  | 2.0 | 12        |
| 42 | Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.  | 1.4 | 32        |
| 43 | The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2. | 0.2 | 9         |
| 44 | Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.   | 0.6 | 3         |
| 45 | Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.  | 2.5 | 13        |
| 46 | Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.  | 0.6 | 2         |
| 47 | Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.   | 2.0 | 21        |
| 48 | Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.                                 | 0.8 | 53        |
| 49 | The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.                              | 0.6 | 6         |
| 50 | Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.  | 2.0 | 8         |
| 51 | Supportive care in multiple myeloma: Current practices and advances. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100476.  | 0.7 | 5         |
| 52 | Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, . .  | 2.0 | 6         |
| 53 | Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021, 105, 1615-1624.   | 0.5 | 0         |
| 54 | "Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1639-1639.  | 0.6 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.                 | 0.6 | 0         |
| 56 | An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFN $\gamma$ -NIS). <i>Blood</i> , 2021, 138, 1333-1333.          | 0.6 | 0         |
| 57 | Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.  | 0.6 | 0         |
| 58 | Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio $\geq$ 100. <i>Blood</i> , 2021, 138, 1617-1617.                       | 0.6 | 0         |
| 59 | Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021, 138, 819-819.   | 0.6 | 1         |
| 60 | Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021, 138, 3805-3805.   | 0.6 | 0         |
| 61 | Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.               | 2.8 | 8         |
| 62 | Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3760-3760.   | 0.6 | 1         |
| 63 | Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. <i>Blood</i> , 2021, 138, 3773-3773.  | 0.6 | 0         |
| 64 | Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021, 138, 3761-3761.                     | 0.6 | 0         |
| 65 | Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 1632-1632.                         | 0.6 | 0         |
| 66 | Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 3774-3774.                   | 0.6 | 1         |
| 67 | The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1619-1619.  | 0.6 | 0         |
| 68 | Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021, 138, 543-543. | 0.6 | 0         |
| 69 | Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021, 138, 1630-1630.                             | 0.6 | 0         |
| 70 | Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021, 138, 119-119.  | 0.6 | 0         |
| 71 | The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021, 138, 2650-2650.                            | 0.6 | 0         |
| 72 | “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma” the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, 196.             | 2.8 | 28        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16. | 1.4 | 25        |
| 74 | Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.   | 0.8 | 161       |
| 75 | Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, E8-E10.  | 2.0 | 10        |
| 76 | Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.   | 2.0 | 14        |
| 77 | Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.  | 0.2 | 8         |
| 78 | Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.  | 2.0 | 37        |
| 79 | Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.   | 2.0 | 4         |
| 80 | Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of WaldenstrÃm Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.   | 2.0 | 33        |
| 81 | IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.   | 3.3 | 40        |
| 82 | Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020, 34, 1472-1475.  | 3.3 | 15        |
| 83 | Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.  | 3.3 | 29        |
| 84 | Colon perforation in multiple myeloma patients â€ A complication of highâ€dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.   | 1.3 | 3         |
| 85 | Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.   | 3.2 | 32        |
| 86 | Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.   | 2.8 | 3         |
| 87 | Predictors of short-term survival in WaldenstrÃm Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.   | 0.6 | 2         |
| 88 | Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.   | 2.0 | 17        |
| 89 | Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.  | 2.5 | 58        |
| 90 | Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.  | 2.8 | 59        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.  | 2.8 | 12        |
| 92  | Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137. | 1.3 | 8         |
| 93  | Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1402-1405.            | 2.0 | 4         |
| 94  | The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, 52.   | 2.8 | 8         |
| 95  | Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 55.  | 2.8 | 36        |
| 96  | Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.   | 1.3 | 5         |
| 97  | Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a "graft versus host"-like syndrome and poor outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 1879-1881.          | 1.3 | 1         |
| 98  | Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.  | 2.0 | 12        |
| 99  | Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.      | 2.0 | 19        |
| 100 | Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 20.   | 2.8 | 26        |
| 101 | Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.   | 2.8 | 18        |
| 102 | Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.  | 2.0 | 35        |
| 103 | Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.   | 0.2 | 15        |
| 104 | Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 322-326.  | 2.5 | 8         |
| 105 | A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 41.  | 2.8 | 24        |
| 106 | Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 52-53.  | 0.6 | 4         |
| 107 | MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.  | 0.6 | 2         |
| 108 | Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.  | 0.6 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.  | 0.6 | 4         |
| 110 | Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8. | 0.6 | 1         |
| 111 | Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 12-13.  | 0.6 | 3         |
| 112 | Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020, 136, 22-23.   | 0.6 | 1         |
| 113 | Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20506-e20506.   | 0.8 | 0         |
| 114 | Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20510-e20510.  | 0.8 | 1         |
| 115 | Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8549-8549.   | 0.8 | 0         |
| 116 | Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20515-e20515.   | 0.8 | 0         |
| 117 | Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.  | 0.6 | 0         |
| 118 | The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020, 136, 9-10.  | 0.6 | 0         |
| 119 | A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.  | 0.6 | 0         |
| 120 | Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. <i>Blood</i> , 2020, 136, 34-35.   | 0.6 | 0         |
| 121 | Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020, 136, 15-16.   | 0.6 | 0         |
| 122 | Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 14-15.   | 0.6 | 0         |
| 123 | Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 6-7.   | 0.6 | 0         |
| 124 | Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-22.  | 0.6 | 0         |
| 125 | A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 21-22.   | 0.6 | 0         |
| 126 | Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. <i>Blood</i> , 2020, 136, 12-13.  | 0.6 | 0         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.   | 0.6 | 1         |
| 128 | Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020, 136, 37-38.  | 0.6 | 0         |
| 129 | Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-2.  | 0.6 | 0         |
| 130 | Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.  | 0.6 | 0         |
| 131 | Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.  | 2.0 | 18        |
| 132 | Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.   | 1.3 | 9         |
| 133 | Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019, 54, 442-447.  | 1.3 | 7         |
| 134 | Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.   | 1.3 | 81        |
| 135 | Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.  | 1.2 | 40        |
| 136 | Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102. | 1.4 | 9         |
| 137 | Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.   | 2.0 | 7         |
| 138 | Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1020-1026.   | 2.0 | 36        |
| 139 | Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, 1066-1071.   | 2.0 | 14        |
| 140 | Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.   | 3.3 | 22        |
| 141 | Sporadic late-onset nemaline myopathy. <i>Neurology</i> , 2019, 93, e298-e305.  | 1.5 | 45        |
| 142 | The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.   | 1.3 | 9         |
| 143 | Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.  | 0.6 | 4         |
| 144 | Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1520-1525.  | 2.0 | 9         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.   | 1.2 | 17        |
| 146 | Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.  | 2.8 | 38        |
| 147 | Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.   | 1.3 | 9         |
| 148 | Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.  | 2.0 | 15        |
| 149 | Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.   | 1.2 | 12        |
| 150 | Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.  | 3.3 | 7         |
| 151 | Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.  | 2.0 | 17        |
| 152 | Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.   | 3.3 | 12        |
| 153 | A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.   | 1.4 | 59        |
| 154 | Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.   | 2.5 | 41        |
| 155 | Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiparametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.   | 2.0 | 11        |
| 156 | Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.  | 2.0 | 20        |
| 157 | Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.   | 1.3 | 7         |
| 158 | Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. <i>Leukemia and Lymphoma</i> , 2019, 60, 1275-1282. | 0.6 | 7         |
| 159 | Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.  | 3.3 | 28        |
| 160 | Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.  | 3.3 | 20        |
| 161 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.  | 6.3 | 187       |
| 162 | Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.  | 3.3 | 36        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.  | 3.3 | 72        |
| 164 | Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.  | 0.6 | 2         |
| 165 | Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.  | 0.6 | 1         |
| 166 | A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019, 134, 1846-1846.  | 0.6 | 2         |
| 167 | Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.   | 0.6 | 2         |
| 168 | Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 864-864.  | 0.6 | 13        |
| 169 | Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019, 134, 1905-1905.  | 0.6 | 2         |
| 170 | Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7509-7509. | 0.8 | 4         |
| 171 | E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8001-8001.   | 0.8 | 17        |
| 172 | Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8039-8039.  | 0.8 | 31        |
| 173 | Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19519-e19519.  | 0.8 | 2         |
| 174 | Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.  | 1.4 | 16        |
| 175 | Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8011-8011.  | 0.8 | 0         |
| 176 | Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019, 134, 4505-4505.  | 0.6 | 0         |
| 177 | Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019, 134, 5523-5523.   | 0.6 | 0         |
| 178 | Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.  | 0.6 | 0         |
| 179 | Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 4396-4396.  | 0.6 | 0         |
| 180 | Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019, 134, 3080-3080.  | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.   | 0.6 | 0         |
| 182 | Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. <i>Blood</i> , 2019, 134, 1904-1904.  | 0.6 | 0         |
| 183 | Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5532-5532.   | 0.6 | 0         |
| 184 | Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019, 134, 3171-3171.  | 0.6 | 1         |
| 185 | A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.  | 0.6 | 1         |
| 186 | The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 2197-2197.   | 0.6 | 0         |
| 187 | Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.   | 0.6 | 1         |
| 188 | Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.   | 3.3 | 8         |
| 189 | Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.   | 3.3 | 64        |
| 190 | Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018, 103, 1229-1234.   | 1.7 | 10        |
| 191 | Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 889-894.  | 2.0 | 14        |
| 192 | Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2127-2132. | 2.0 | 21        |
| 193 | Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia. <i>Neurology</i> , 2018, 90, 748-752.  | 1.5 | 8         |
| 194 | Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.  | 0.8 | 71        |
| 195 | Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. <i>Leukemia</i> , 2018, 32, 1414-1420.   | 3.3 | 20        |
| 196 | Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.  | 3.3 | 28        |
| 197 | Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.  | 1.3 | 4         |
| 198 | Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 182, 71-77.   | 1.2 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 86-92. | 1.4 | 57        |
| 200 | Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 179-186.  | 2.0 | 49        |
| 201 | <i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.   | 2.0 | 57        |
| 202 | Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t(11;14). <i>European Journal of Haematology</i> , 2018, 100, 215-217.  | 1.1 | 52        |
| 203 | Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.  | 2.0 | 11        |
| 204 | POEMS Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 119-139.   | 0.9 | 28        |
| 205 | Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018, 36, 1323-1329.   | 0.8 | 100       |
| 206 | Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.  | 2.8 | 16        |
| 207 | Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 116.  | 2.8 | 64        |
| 208 | Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. <i>Blood Cancer Journal</i> , 2018, 8, 125.  | 2.8 | 29        |
| 209 | Utility and prognostic value of <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 1518-1523.   | 2.0 | 19        |
| 210 | Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 769-776.   | 2.5 | 23        |
| 211 | Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018, 2, 3149-3154.   | 2.5 | 23        |
| 212 | Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2360-2364.  | 2.0 | 14        |
| 213 | Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2157-2159.   | 2.0 | 8         |
| 214 | Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 70.   | 2.8 | 18        |
| 215 | Serum free light chain measurements to reduce 24h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.  | 2.0 | 3         |
| 216 | Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.  | 2.0 | 24        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.   | 2.8 | 171       |
| 218 | Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. Blood, 2018, 132, 123-123. | 0.6 | 6         |
| 219 | Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.  | 0.6 | 10        |
| 220 | IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.  | 0.6 | 1         |
| 221 | Natural history of delp53 multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20017-e20017.   | 0.8 | 0         |
| 222 | Predictors of disease progression in smoldering Waldenström macroglobulinemia.. Journal of Clinical Oncology, 2018, 36, 7571-7571.  | 0.8 | 0         |
| 223 | Long-Term Survivorship with Active Multiple Myeloma. Blood, 2018, 132, 1912-1912.   | 0.6 | 0         |
| 224 | Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.   | 0.6 | 0         |
| 225 | Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.   | 0.6 | 1         |
| 226 | Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.  | 0.6 | 2         |
| 227 | Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.  | 0.6 | 0         |
| 228 | Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.  | 0.6 | 0         |
| 229 | Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.   | 0.6 | 0         |
| 230 | Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. Blood, 2018, 132, 2147-2147.                               | 0.6 | 0         |
| 231 | Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.   | 0.6 | 0         |
| 232 | Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.  | 0.6 | 1         |
| 233 | Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy. Blood, 2018, 132, 4613-4613.  | 0.6 | 0         |
| 234 | Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.   | 0.6 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , 2018, 132, 4502-4502.   | 0.6 | 0         |
| 236 | Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 1902-1902.  | 0.6 | 1         |
| 237 | Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018, 132, 5594-5594.   | 0.6 | 0         |
| 238 | Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018, 132, 3227-3227.   | 0.6 | 0         |
| 239 | Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018, 132, 5610-5610.  | 0.6 | 0         |
| 240 | Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018, 132, 4138-4138.  | 0.6 | 0         |
| 241 | Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018, 132, 3268-3268. | 0.6 | 0         |
| 242 | Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018, 132, 3436-3436.  | 0.6 | 0         |
| 243 | Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.   | 0.6 | 1         |
| 244 | Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.   | 0.6 | 0         |
| 245 | Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 3160-3160.  | 0.6 | 2         |
| 246 | Prognosis of Patients with Waldenstrom Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.   | 0.6 | 1         |
| 247 | Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. <i>Blood</i> , 2018, 132, 719-719.  | 0.6 | 1         |
| 248 | Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.  | 0.6 | 16        |
| 249 | Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.  | 2.0 | 47        |
| 250 | Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.  | 1.5 | 45        |
| 251 | Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.  | 2.0 | 16        |
| 252 | Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.  | 0.6 | 249       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.                                 | 1.4 | 4         |
| 254 | Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.                     | 1.4 | 1         |
| 255 | Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. <i>Leukemia</i> , 2017, 31, 2791-2798.  | 3.3 | 120       |
| 256 | Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e569-e569.   | 2.8 | 8         |
| 257 | The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.   | 2.0 | 5         |
| 258 | Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.   | 2.0 | 75        |
| 259 | Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.   | 1.4 | 115       |
| 260 | Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.   | 2.0 | 24        |
| 261 | Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.   | 3.4 | 110       |
| 262 | First report of MYD88 <sup>L265P</sup> somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43.                     | 1.4 | 10        |
| 263 | Delineation of the timing of second-line therapy post autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017, 130, 1578-1584.  | 0.6 | 21        |
| 264 | Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1087-1091.  | 0.7 | 2         |
| 265 | A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1372-1377.   | 1.3 | 13        |
| 266 | Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.  | 1.2 | 15        |
| 267 | Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017, 102, 1439-1445.   | 1.7 | 29        |
| 268 | Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.   | 1.2 | 25        |
| 269 | Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.  | 2.0 | 25        |
| 270 | Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188. | 1.4 | 4         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 271 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.   | 0.6 | 54        |
| 272 | Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. <i>American Journal of Hematology</i> , 2017, 92, E15-E17.                                     | 2.0 | 20        |
| 273 | Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.   | 2.0 | 41        |
| 274 | Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.  | 1.4 | 72        |
| 275 | Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8038-8038.                                 | 0.8 | 1         |
| 276 | Natural history of t(11;14) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8014-8014.  | 0.8 | 1         |
| 277 | The use of proteasome inhibitors among patients with POEMS syndrome.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19530-e19530.  | 0.8 | 0         |
| 278 | Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8020-8020. | 0.8 | 0         |
| 279 | Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19532-e19532.  | 0.8 | 0         |
| 280 | Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations. <i>American Journal of Hematology</i> , 2016, 91, E5-E6.                   | 2.0 | 3         |
| 281 | Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205.  | 2.0 | 37        |
| 282 | Induction therapy pre autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.  | 2.0 | 45        |
| 283 | Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e454-e454.  | 2.8 | 56        |
| 284 | Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.   | 1.7 | 9         |
| 285 | The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016, 44, 32-39.  | 0.4 | 22        |
| 286 | Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.  | 0.2 | 38        |
| 287 | Systemic Immunoglobulin Light Chain Amyloidosisâ€“Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.  | 1.4 | 43        |
| 288 | Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.  | 2.0 | 76        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.   | 2.0 | 57        |
| 290 | N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.                            | 2.0 | 71        |
| 291 | First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.  | 0.6 | 17        |
| 292 | Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.   | 2.0 | 30        |
| 293 | The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.                                 | 0.4 | 25        |
| 294 | Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.  | 0.6 | 1         |
| 295 | Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.  | 0.6 | 4         |
| 296 | Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.   | 0.6 | 2         |
| 297 | Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.  | 0.6 | 1         |
| 298 | Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.   | 0.6 | 3         |
| 299 | Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. Blood, 2016, 128, 3337-3337.                                    | 0.6 | 5         |
| 300 | Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. Blood, 2016, 128, 3444-3444.  | 0.6 | 1         |
| 301 | Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.              | 0.6 | 1         |
| 302 | Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2016, 34, 8002-8002.  | 0.8 | 5         |
| 303 | Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. Journal of Clinical Oncology, 2016, 34, 8004-8004.   | 0.8 | 3         |
| 304 | Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. Journal of Clinical Oncology, 2016, 34, 8015-8015. | 0.8 | 1         |
| 305 | Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).. Journal of Clinical Oncology, 2016, 34, 8058-8058.   | 0.8 | 4         |
| 306 | The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. Journal of Clinical Oncology, 2016, 34, 8033-8033.  | 0.8 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 307 | Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8053-8053.     | 0.8 | 0         |
| 308 | Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8017-8017.  | 0.8 | 0         |
| 309 | Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2016, 34, 7552-7552.     | 0.8 | 1         |
| 310 | Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. Journal of Clinical Oncology, 2016, 34, 8062-8062.   | 0.8 | 0         |
| 311 | Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. Journal of Clinical Oncology, 2016, 34, 8016-8016.  | 0.8 | 0         |
| 312 | Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2016, 128, 5615-5615.   | 0.6 | 0         |
| 313 | A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2016, 128, 996-996. | 0.6 | 0         |
| 314 | Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. Blood, 2016, 128, 3273-3273.                             | 0.6 | 0         |
| 315 | Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.   | 0.6 | 0         |
| 316 | Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. Blood, 2016, 128, 5480-5480.  | 0.6 | 1         |
| 317 | Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. Blood, 2016, 128, 1810-1810.  | 0.6 | 0         |
| 318 | Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.  | 0.6 | 0         |
| 319 | The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.   | 0.6 | 0         |
| 320 | Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. Blood, 2016, 128, 3269-3269.          | 0.6 | 0         |
| 321 | Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.                                     | 0.6 | 0         |
| 322 | Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.                             | 0.6 | 0         |
| 323 | Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.   | 0.6 | 0         |
| 324 | Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2016, 128, 2267-2267.                                   | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 325 | Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology, 2015, 90, 1106-1110.   | 2.0 | 19        |
| 326 | Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.   | 2.0 | 18        |
| 327 | Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American Journal of Hematology, 2015, 90, 981-985.   | 2.0 | 38        |
| 328 | Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.  | 0.6 | 36        |
| 329 | Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer Journal, 2015, 5, e364-e364.   | 2.8 | 81        |
| 330 | Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer Journal, 2015, 5, e363-e363.  | 2.8 | 36        |
| 331 | Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.   | 1.4 | 92        |
| 332 | Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.  | 1.4 | 106       |
| 333 | Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 349-357.e2.  | 0.2 | 10        |
| 334 | Soluble suppression of tumorigenicity 2 (sTSG2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. American Journal of Hematology, 2015, 90, 524-528.   | 2.0 | 31        |
| 335 | Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. Blood, 2015, 126, 1830-1830.  | 0.6 | 1         |
| 336 | Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients. Blood, 2015, 126, 3046-3046.   | 0.6 | 1         |
| 337 | Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood, 2015, 126, 3050-3050.   | 0.6 | 8         |
| 338 | Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. Blood, 2015, 126, 3177-3177.  | 0.6 | 3         |
| 339 | Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. Blood, 2015, 126, 4197-4197.  | 0.6 | 5         |
| 340 | Thrombotic Microangiopathy in Multiple Myeloma. Blood, 2015, 126, 5317-5317.  | 0.6 | 3         |
| 341 | Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). Blood, 2015, 126, 727-727. | 0.6 | 32        |
| 342 | Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment.. Journal of Clinical Oncology, 2015, 33, 8594-8594.  | 0.8 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 343 | Higher CD3 cell counts in apheresis collection in relation to superior survival in patients with multiple myeloma.. Journal of Clinical Oncology, 2015, 33, 11085-11085.   | 0.8 | 0         |
| 344 | Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).. Journal of Clinical Oncology, 2015, 33, 8595-8595.        | 0.8 | 0         |
| 345 | Survival trends in young patients with Waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2015, 33, 8596-8596.   | 0.8 | 0         |
| 346 | Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. Blood, 2015, 126, 3039-3039.   | 0.6 | 0         |
| 347 | AL Amyloidosis and Patient Reported Quality of Life. Blood, 2015, 126, 3317-3317.  | 0.6 | 0         |
| 348 | Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. Blood, 2015, 126, 4176-4176.  | 0.6 | 0         |
| 349 | The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Blood, 2015, 126, 3044-3044.   | 0.6 | 0         |
| 350 | Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology, 2014, 92, 485-490.                 | 1.1 | 23        |
| 351 | Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. Biology of Blood and Marrow Transplantation, 2014, 20, 222-228. | 2.0 | 36        |
| 352 | Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933.   | 1.4 | 240       |
| 353 | Outcomes of young patients with Waldenstrom macroglobulinemia (WM).. Journal of Clinical Oncology, 2014, 32, 8609-8609.  | 0.8 | 1         |
| 354 | Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2013, 19, 87-93.                  | 2.0 | 76        |
| 355 | Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.      | 1.4 | 440       |
| 356 | Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.   | 0.8 | 147       |
| 357 | Survival Outcomes Of Very Young (<40 years) Myeloma Patients. Blood, 2013, 122, 2136-2136.   | 0.6 | 3         |
| 358 | Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.   | 0.6 | 1         |
| 359 | Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.  | 0.6 | 2         |
| 360 | Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.  | 0.6 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 361 | A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort. Blood, 2013, 122, 3179-3179.   | 0.6 | 13        |
| 362 | Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. Blood, 2013, 122, 3210-3210.  | 0.6 | 7         |
| 363 | Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Blood, 2013, 122, 407-407.  | 0.6 | 12        |
| 364 | Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.   | 0.6 | 9         |
| 365 | Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.  | 0.6 | 0         |
| 366 | Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.   | 0.6 | 0         |
| 367 | Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. Blood, 2013, 122, 754-754.   | 0.6 | 0         |
| 368 | Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs. Blood, 2013, 122, 1928-1928.           | 0.6 | 0         |
| 369 | Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. Blood, 2013, 122, 1842-1842.                                | 0.6 | 0         |
| 370 | Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.  | 0.8 | 837       |
| 371 | Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood, 2012, 119, 5397-5404.  | 0.6 | 144       |
| 372 | Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood, 2012, 119, 4860-4867.   | 0.6 | 119       |
| 373 | Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood, 2012, 119, 2100-2105.   | 0.6 | 218       |
| 374 | Tenâ€year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer, 2012, 118, 6105-6109.   | 2.0 | 57        |
| 375 | Case vignettes and other brain teasers of monoclonal gammopathies. Hematology American Society of Hematology Education Program, 2012, 2012, 582-585.  | 0.9 | 4         |
| 376 | Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. Blood, 2012, 120, 1858-1858.   | 0.6 | 2         |
| 377 | Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. Blood, 2012, 120, 201-201.   | 0.6 | 16        |
| 378 | Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.. Blood, 2012, 120, 2965-2965. | 0.6 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. Blood, 2012, 120, 3138-3138.  | 0.6 | 26        |
| 380 | Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.   | 0.6 | 7         |
| 381 | Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. Blood, 2012, 120, 3992-3992.  | 0.6 | 1         |
| 382 | Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.   | 0.6 | 1         |
| 383 | Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. Blood, 2012, 120, 2973-2973.       | 0.6 | 16        |
| 384 | Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.  | 0.6 | 0         |
| 385 | Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). Blood, 2012, 120, 600-600. | 0.6 | 0         |
| 386 | Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. Blood, 2012, 120, 599-599.  | 0.6 | 0         |
| 387 | Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.   | 0.6 | 0         |
| 388 | Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings, 2011, 86, 12-18.   | 1.4 | 164       |
| 389 | High prevalence of polyclonal hypergammaglobulinemia in adult males in Ghana, Africa. American Journal of Hematology, 2011, 86, 554-558.   | 2.0 | 10        |
| 390 | Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplantation, 2011, 46, 943-949.   | 1.3 | 57        |
| 391 | The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.  | 0.6 | 1         |
| 392 | Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.  | 0.6 | 2         |
| 393 | Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. Blood, 2011, 118, 2950-2950.   | 0.6 | 1         |
| 394 | A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Blood, 2011, 118, 3095-3095.  | 0.6 | 1         |
| 395 | Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. Blood, 2011, 118, 3963-3963.  | 0.6 | 4         |
| 396 | Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 3981-3981.  | 0.6 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 397 | Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. Blood, 2011, 118, 806-806.                          | 0.6 | 1         |
| 398 | The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4120-4120.   | 0.6 | 5         |
| 399 | Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. Blood, 2011, 118, 3101-3101.  | 0.6 | 0         |
| 400 | Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. Blood, 2011, 118, 2992-2992.                        | 0.6 | 0         |
| 401 | The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. Blood, 2011, 118, 2868-2868.   | 0.6 | 8         |
| 402 | Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine. Blood, 2011, 118, 636-636.  | 0.6 | 0         |
| 403 | Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. Blood, 2011, 118, 1875-1875.  | 0.6 | 2         |
| 404 | IgD Amyloidosis: An Unrecognized Entity. Blood, 2011, 118, 5079-5079.  | 0.6 | 0         |
| 405 | A case of bilateral renal arterial thrombosis associated with cryocryoglobulinaemia. CKJ: Clinical Kidney Journal, 2010, 3, 74-77.   | 1.4 | 17        |
| 406 | Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score. Blood, 2010, 116, 1892-1892.   | 0.6 | 2         |
| 407 | Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. Blood, 2010, 116, 1893-1893.   | 0.6 | 1         |
| 408 | Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. Blood, 2010, 116, 1964-1964.   | 0.6 | 5         |
| 409 | Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). Blood, 2010, 116, 3031-3031. | 0.6 | 5         |
| 410 | Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. Blood, 2010, 116, 3557-3557.  | 0.6 | 1         |
| 411 | Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. Blood, 2010, 116, 370-370.  | 0.6 | 4         |
| 412 | Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. Blood, 2010, 116, 863-863.   | 0.6 | 1         |
| 413 | Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). Blood, 2010, 116, 985-985.  | 0.6 | 12        |
| 414 | Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.   | 0.6 | 0         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 415 | Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. <i>Blood</i> , 2010, 116, 3047-3047.                        | 0.6 | 0         |
| 416 | Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. <i>Blood</i> , 2010, 116, 1942-1942.                              | 0.6 | 2         |
| 417 | Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. <i>Blood</i> , 2010, 116, 4518-4518.   | 0.6 | 0         |
| 418 | Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. <i>Blood</i> , 2010, 116, 2253-2253.   | 0.6 | 5         |
| 419 | Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function. <i>Blood</i> , 2010, 116, 2970-2970.  | 0.6 | 1         |
| 420 | A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2010, 116, 987-987.  | 0.6 | 1         |
| 421 | Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. <i>Blood</i> , 2010, 116, 3468-3468.                                     | 0.6 | 0         |
| 422 | Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma. <i>Blood</i> , 2010, 116, 1958-1958.                     | 0.6 | 0         |
| 423 | Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. <i>Blood</i> , 2010, 116, 3554-3554.   | 0.6 | 13        |
| 424 | Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. <i>Blood</i> , 2010, 116, 3469-3469.  | 0.6 | 0         |
| 425 | Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 3572-3572. | 0.6 | 6         |
| 426 | Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 43.   | 2.0 | 1         |
| 427 | Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2868-2868.                   | 0.6 | 3         |
| 428 | Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. <i>Blood</i> , 2009, 114, 956-956.                    | 0.6 | 1         |
| 429 | Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3884-3884.   | 0.6 | 0         |
| 430 | Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008, 111, 2516-2520.   | 0.6 | 2,022     |
| 431 | Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients. <i>Blood</i> , 2008, 112, 2744-2744.   | 0.6 | 6         |
| 432 | Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. <i>Blood</i> , 2008, 112, 95-95.                                  | 0.6 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 433 | Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma.. Blood, 2008, 112, 2301-2301. | 0.6 | 0         |
| 434 | The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome. Blood, 2008, 112, 5114-5114.                                 | 0.6 | 0         |
| 435 | 14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. Blood, 2007, 110, 2477-2477.          | 0.6 | 1         |
| 436 | Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. Blood, 2007, 110, 3608-3608.   | 0.6 | 0         |
| 437 | Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.                  | 0.6 | 0         |
| 438 | Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. Blood, 2007, 110, 2995-2995.  | 0.6 | 0         |
| 439 | Polyclonal Hypergammaglobulinemia in a Randomized Sample of Ghanaian Adult Males.. Blood, 2007, 110, 960-960.   | 0.6 | 0         |